Promising Findings from Aspen Neuroscience's ASPIRO Clinical Trial for Parkinson's Disease Aspen Neuroscience presents positive results from its ASPIRO trial at the AD/PD 2026 conference, showing significant benefits for Parkinson's patients.

Promising Findings from Aspen Neuroscience's ASPIRO Clinical Trial for Parkinson's Disease #USA #San_Diego #Parkinson's_Disease #Aspen_Neuroscience #Sasineprocel

Aspen Neuroscience's Sasineprocel Paves the Way for Innovative Parkinson's Treatment Discover how Aspen Neuroscience's Sasineprocel is set to revolutionize Parkinson's treatment by using a patient's own cells, eliminating immune suppression.

Aspen Neuroscience's Sasineprocel Paves the Way for Innovative Parkinson's Treatment #United_States #San_Diego #Parkinson's_Disease #Aspen_Neuroscience #Sasineprocel

Aspen Neuroscience's Milestone Achievements in Parkinson's Disease Therapy and Manufacturing Aspen Neuroscience announces the completion of Phase 1/2a ASPIRO trial dosing and advances in manufacturing for Parkinson's disease therapy.

Aspen Neuroscience's Milestone Achievements in Parkinson's Disease Therapy and Manufacturing #United_States #San_Diego #Parkinson's_Disease #Aspen_Neuroscience #ANPD001

Aspen Neuroscience Strengthens Leadership with New Chief Medical and Commercial Officers Aspen Neuroscience announces the appointment of new CMO and CCO to enhance the development and readiness of their Parkinson's disease therapies.

Aspen Neuroscience Strengthens Leadership with New Chief Medical and Commercial Officers #USA #San_Diego #Parkinson's_Disease #Aspen_Neuroscience #Revati_Shreeniwas

Aspen Neuroscience Secures $115 Million Funding for Personalized Cell Therapy Innovations Aspen Neuroscience, Inc. has announced the closing of a $115 million Series C financing round aimed at enhancing personalized regenerative therapies for Parkinson's disease.

Aspen Neuroscience Secures $115 Million Funding for Personalized Cell Therapy Innovations #USA #San_Diego #Parkinson's_Disease #Aspen_Neuroscience #ANPD001

Aspen Neuroscience Launches Cohort 3 in Pioneering Parkinson's Disease Trial with ANPD001 Aspen Neuroscience has begun Cohort 3 in its ASPIRO trial, showcasing the commercial formulation of ANPD001, a promising treatment for Parkinson's Disease.

Aspen Neuroscience Launches Cohort 3 in Pioneering Parkinson's Disease Trial with ANPD001 #United_States #San_Diego #Parkinson's_Disease #Aspen_Neuroscience #ANPD001

Aspen Neuroscience to Showcase Innovative Parkinson's Treatment at ISSCR 2025 Aspen Neuroscience will present groundbreaking findings on Parkinson's Disease therapies at the ISSCR 2025 Annual Meeting in Hong Kong, highlighting their innovative iPSC-derived approaches.

Aspen Neuroscience to Showcase Innovative Parkinson's Treatment at ISSCR 2025 #United_States #San_Diego #Parkinson's_Disease #Aspen_Neuroscience #ISSCR_2025

Aspen Neuroscience Showcases Innovative Approaches at the ASGCT Annual Meeting in New Orleans At the ASGCT Annual Meeting, Aspen Neuroscience highlights groundbreaking research into neuron replacement therapy for Parkinson's Disease.

Aspen Neuroscience Showcases Innovative Approaches at the ASGCT Annual Meeting in New Orleans #United_States #New_Orleans #Parkinson's_Disease #Aspen_Neuroscience #iPSC_Neuron_Therapy

Aspen Neuroscience Showcases Breakthrough in Parkinson's Cell Therapy at ISCT Annual Meeting Aspen Neuroscience will present innovative advancements in iPSC-derived neuron replacement therapies for Parkinson's disease at the ISCT Annual Meeting in New Orleans.

Aspen Neuroscience Showcases Breakthrough in Parkinson's Cell Therapy at ISCT Annual Meeting #United_States #New_Orleans #Parkinson's_Disease #Aspen_Neuroscience #iPSC-derived

Dalen Meeter Takes on CFO Role at Aspen Neuroscience to Drive Growth and Innovation Aspen Neuroscience has announced the appointment of Dalen Meeter as CFO, bringing his expertise to advance innovative therapies for Parkinson's disease.

Dalen Meeter Takes on CFO Role at Aspen Neuroscience to Drive Growth and Innovation #United_States #San_Diego #biotechnology #Aspen_Neuroscience #Dalen_Meeter

Aspen Neuroscience Expands Automated Production for Parkinson's Cell Therapy Aspen Neuroscience is enhancing its automated production process for ANPD001, a cell therapy for Parkinson's. This expansion aims to increase capacity and streamline operations at their San Diego facility.

Aspen Neuroscience Expands Automated Production for Parkinson's Cell Therapy #United_States #San_Diego #Aspen_Neuroscience #ANPD001 #Myatos